New hope for frail lung cancer patients: immune drug may delay tumor growth
NCT ID NCT05617963
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether the immune-boosting drug durvalumab can help frail patients with limited-stage small cell lung cancer keep their disease from progressing after standard chemoradiotherapy. About 100 participants who have stable or improved disease after initial treatment will receive durvalumab every 4 weeks for up to 24 months. The study focuses on patients who are older, have a weaker performance status, or could not receive full concurrent chemoradiation due to other health issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (a drug that helps the immune system fight cancer)
What this could lead to
If it works, this could offer a way to keep lung cancer from worsening in frail patients who have limited treatment options.
What could go wrong
This is a small, early-phase trial with only 100 participants. The drug may not improve survival and could cause side effects like immune-related inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM - Hôpital Nord
Marseille, France
-
CARIO
Plérin, France
-
CH Saint Brieuc
Saint-Brieuc, France
-
CH de la côte Basque
Bayonne, France
-
CHI Créteil
Créteil, France
-
CHU Dupuytren
Limoges, France
-
CHU de CAEN
Caen, France
-
Centre François Baclesse
Caen, France
-
Centre George François Leclerc
Dijon, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier du Pays d'Aix
Aix-en-Provence, France
-
Centre Jean Perrin
Clermont-Ferrand, France
-
Centre Lacassagne
Nice, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar Lambret
Lille, France
-
Centre d'Oncologie du Pays Basque
Bayonne, France
-
Centre d'oncologie Saint Yves
Vannes, France
-
Centre de Radiothérapie du Pays d'Aix
Aix-en-Provence, France
-
Clinique Belharra
Bayonne, France
-
Clinique Mutualiste de l'Estuaire
Saint-Nazaire, France
-
Groupe Hospitalier Bretagne Sud
Lorient, France
-
Hopital Nord Ouest - Villefranche sur Saône
Villefranche-sur-Saône, France
-
Hopital européen Marseille
Marseille, France
-
Hopital privé Clairval
Marseille, France
-
Hopital privé du Confluent
Nantes, France
-
Hôpital Tenon APHP
Paris, France
-
Institut Curie
Paris, France
-
Institut Godinot
Reims, France
-
Institut Paoli-Calmettes
Marseille, France
-
Institut du Cancer Avignon-Provence
Avignon, France
-
Institut régional du Cancer de Montpellier - ICM Val d'Aurelle
Montpellier, France
-
Polyclinique de Limoges -Site Clinique Chénieux
Limoges, France